# Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors

> **NCT03627403** · PHASE2 · TERMINATED · sponsor: **University of Utah** · enrollment: 17 (actual)

## Conditions studied

- Primary Myelofibrosis
- Post-essential Thrombocythemia Myelofibrosis
- Post-polycythemia Vera Myelofibrosis

## Interventions

- **DRUG:** Selinexor

## Key facts

- **NCT ID:** NCT03627403
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-10
- **Primary completion:** 2023-08-16
- **Final completion:** 2025-03-05
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** PI and Sponsor decision. Accrual was low and there was sufficient data to detect a response.
- **Last updated:** 2025-06-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03627403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03627403, "Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03627403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*